-
Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 release
de Jong, M., Veth, M., Brachtlová, T., King, L. A., Saura-Esteller, J., Bechler, T. M., van Helden, P. M., Alhan, C., Lameris, R., de Gruijl, T. D. & van der Vliet, J. J., 28 Jun 2026, In: Journal for Immunotherapy of Cancer. 14, 6Research output: Contribution to Journal › Article › Academic › peer-review
-
A trophoblast glycoprotein specific 5T4-Vδ2 bispecific T cell engager recruits Vγ9Vδ2-T cells for tumor-selective cytotoxicity across solid malignancies
de Jong, M., Žiberna, R., Veth, M., Michielon, E., Myrda, J., Seidel, J., Akbarzadeh, M., van Helden, P. M., Vis, A. N., Derks, S., Lameris, R., de Gruijl, T. D. & van der Vliet, H. J., Jun 2026, In: Clinical immunology (Orlando, Fla.). 285, p. 110707 110707.Research output: Contribution to Journal › Article › Academic › peer-review
-
Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansion
King, L. A., de Jong, M., Veth, M., Lutje Hulsik, D., Yousefi, P., Iglesias-Guimarais, V., van Helden, P. M., de Gruijl, T. D. & van der Vliet, H. J., 2024, In: Frontiers in Oncology. 14, p. 1474007 1474007.Research output: Contribution to Journal › Article › Academic › peer-review
- All publications
